Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?

American Heart Journal

Volumn 168, Issue 5, 2014, Pages 611-621

  Huber, Kurt ^a   Bates, Eric R ^b   Valgimigli, Marco ^c   Wallentin, Lars ^d   Kristensen, Steen Dalby ^e   Anderson, Jeffrey L ^f   Lopez Sendon, Jose Luis ^g   Tubaro, Marco ^h   Granger, Christopher B ⁱ   Bode, Christoph ^j   Ohman, Erik Magnus ⁱ   Steg, Philippe Gabriel ^k,l  

^a WILHELMINEN HOSPITAL   (Austria)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UPPSALA UNIVERSITY   (Sweden)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h SAN FILIPPO NERI HOSPITAL   (Italy)

ⁱ DUKE UNIVERSITY   (United States)

^j UNIVERSITY OF FREIBURG   (Germany)

^k INSERM   (France)

^l BICHAT HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; ELINOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HIRULOG; PEGNIVACOGIN; PRASUGREL; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; VORAPAXAR; ADENOSINE; ADENOSINE PHOSPHATE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; HEPARIN; HIRUDIN DERIVATIVE; LACTONE; PEPTIDE; PEPTIDE FRAGMENT; PIPERAZINE DERIVATIVE; POLYSACCHARIDE; PURINERGIC P2Y RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE; RECOMBINANT PROTEIN; THIOPHENE DERIVATIVE; THROMBIN RECEPTOR; TIROFIBAN; TYROSINE; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLEEDING TENDENCY; DRUG CONTRAINDICATION; DRUG EFFICACY; EMERGENCY TREATMENT; FEMORAL ARTERY; FIBRINOLYTIC THERAPY; HEART ATRIUM FIBRILLATION; HUMAN; INTENSIVE CARE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERSONALIZED MEDICINE; PLATELET REACTIVITY; PRACTICE GUIDELINE; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE FUNCTION; THROMBOSIS PREVENTION; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION;

ACUTE CORONARY SYNDROME; ADENOSINE; ADENOSINE MONOPHOSPHATE; ANTICOAGULANTS; ASPIRIN; DRUG THERAPY, COMBINATION; ENOXAPARIN; HEPARIN; HIRUDINS; HUMANS; LACTONES; PEPTIDE FRAGMENTS; PEPTIDES; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYSACCHARIDES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; PYRIDINES; RECEPTORS, THROMBIN; RECOMBINANT PROTEINS; THIOPHENES; TYROSINE; WARFARIN;

EID: 84908371679     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.06.014     Document Type: Review

References (65)

1. C.W. Hamm, J.-P. Bassand, and S. Agewall ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur Heart J 32 2011 2999 3054
2. H. Jneid, J.L. Anderson, and R.S. Wright 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 60 2012 645 681
3. P.T. O'Gara, F.G. Kushner, and D.D. Ascheim 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 e140
4. P.G. Steg, S.K. James, and D. Atar ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2012 2569 2619
5. R. De Caterina, S. Husted, and L. Wallentin Anticoagulants in heart disease - current status and perspectives. Section I - general background on coagulation and targets of anticoagulants Thromb Haemost 109 2013 569 579
6. D.P. Faxon, J.W. Eikelboom, and P.B. Berger Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective Thromb Haemost 106 2011 572 584
7. G. Lip, K. Huber, and F. Andreotti European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting Thromb Haemost 103 2010 13 28
8. P.G. Steg, K. Huber, and F. Andreotti Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology Eur Heart J 32 2011 1854 1864
9. G. Montalescot, L. Bolognese, and D. Dudek Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes N Engl J Med 369 2013 999 1010
10. K. Huber, and G.Y. Lip Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes Thromb Haemost 110 2013 11 13
11. D. Aradi, R.F. Storey, and A. Komocsi Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention Eur Heart J 35 2013 209 215
12. M.J. Price, P.B. Berger, and P.S. Teirstein Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
13. D. Trenk, G.W. Stone, and M. Gawaz A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI study J Am Coll Cardiol 59 2012 2159 2164
14. J.P. Collet, T. Cuisset, and G. Range Bedside monitoring to adjust antiplatelet therapy for coronary stenting N Engl J Med 367 2012 2100 2109
15. V. Krishna, G.A. Diamond, and S. Kaul Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven Circulation 125 2012 1288 1303 [discussion 1303]
16. J.J. Smit, J.W. van Werkum, and J. ten Berg Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy Heart 96 2010 1815 1820
17. J.M. ten Berg, A.W. van t'Hof, and T. Dill Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome J Am Coll Cardiol 55 2010 2446 2455
18. F. Van de Werf, J. Bax, and A. Betriu Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology Eur Heart J 29 2008 2909 2945
19. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, S. Yusuf, and S.R. Mehta Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med 354 2006 1464 1476
20. S. Yusuf, S.R. Mehta, and S. Chrolavicius Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial JAMA 295 2006 1519 1530
21. P.G. Steg, S.S. Jolly, and S.R. Mehta Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial JAMA 304 2010 1339 1349
22. R. Waksman, O. Bertrand, and M. Driesman Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III) J Interv Cardiol 26 2013 107 113
23. R. Mehran, A.J. Lansky, and B. Witzenbichler Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial Lancet 374 2009 1149 1159
24. G.W. Stone, T. Clayton, and E.N. Deliargris Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: the HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) J Am Coll Cardiol 63 2014 15 20
25. P.G. Steg, A. van 't Hof, and C.W. Hamm Bivalirudin started during emergency transport for primary PCI N Engl J Med 369 2013 2207 2217
26. P.W. Armstrong, A.H. Gershlick, and P. Goldstein Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction N Engl J Med 368 2013 1379 1387
27. S.G. Ellis, M. Tendera, and M.A. de Belder Facilitated PCI in patients with ST-elevation myocardial infarction N Engl J Med 358 2008 2205 2217
28. R.P. Giugliano, J.A. White, and C. Bode Early versus delayed, provisional eptifibatide in acute coronary syndromes N Engl J Med 360 2009 2176 2190
29. H.D. White, D.P. Chew, and H.L. Dauerman Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction Am Heart J 163 2012 182 190 [e4]
30. D. Alexopoulos, I. Xanthopoulou, and V. Gkizas Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 5 2012 797 804
31. A.Y. Fung, J. Saw, and A. Starovoytov Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI randomized trial J Am Coll Cardiol 53 2009 837 845
32. R.A. Harrington, G.W. Stone, and S. McNulty Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2009 2318 2329
33. D.L. Bhatt, A.M. Lincoff, and C.M. Gibson Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2009 2330 2341
34. D.L. Bhatt, G.W. Stone, and K.W. Mahaffey Effect of platelet inhibition with cangrelor during PCI on ischemic events N Engl J Med 368 2013 1303 1313
35. P.G. Steg, D.L. Bhatt, and C.W. Hamm Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data Lancet 382 2013 1981 1992
36. R.C. Welsh, S.V. Rao, and U. Zeymer A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial Circ Cardiovasc Interv 5 2012 336 346
37. M.S. Sabatine, E.M. Antman, and P. Widimsky Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial Lancet 374 2009 787 795
38. P.G. Steg, S.R. Mehta, and C.V. Pollack Jr. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial JAMA 310 2013 1145 1155
39. J.H. Alexander, R.D. Lopes, and S. James Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
40. J.L. Mega, E. Braunwald, and S.D. Wiviott Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19
41. A.J. Camm, G.Y. Lip, and R. De Caterina 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 2012 2719 2747
42. K. Huber, K.J. Airaksinen, and T. Cuisset Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe Thromb Haemost 106 2011 569 571
43. A.K. Niazi, J.J. Dinicolantonio, and C.J. Lavie Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel? Cardiology 126 2013 233 243
44. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
45. C.B. Granger, J.H. Alexander, and J.J. McMurray Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
46. M.R. Patel, K.W. Mahaffey, and J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
47. P. Tricoci, Z. Huang, and C. Held Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N Engl J Med 366 2012 20 33
48. D.A. Morrow, E. Braunwald, and M.P. Bonaca Vorapaxar in the secondary prevention of atherothrombotic events N Engl J Med 366 2012 1404 1413
49. M. Valgimigli, M. Borghesi, and M. Tebaldi Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) Eur Heart J 34 2013 909 919
50. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
51. M.T. Roe, P.W. Armstrong, and K.A. Fox Prasugrel versus clopidogrel for acute coronary syndromes without revascularization N Engl J Med 367 2012 1297 1309
52. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
53. L. Bonello, S. Armero, and O. Ait Mokhtar Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19∗2 loss of function polymorphism J Am Coll Cardiol 56 2010 1630 1636
54. M. Valgimigli, G. Campo, and N. de Cesare Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study Circulation 119 2009 3215 3222
55. C. Viviani Anselmi, C. Briguori, and R. Roncarati Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease JACC Cardiovasc Interv 6 2013 1166 1175
56. 12 inhibitor therapeutic window JACC Cardiovasc Interv 5 2012 290 292
57. B.J. Doyle, C.S. Rihal, and D.A. Gastineau Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice J Am Coll Cardiol 53 2009 2019 2027
58. R.D. Lopes, S. Subherwal, and D.N. Holmes The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction Eur Heart J 33 2012 2044 2053
59. S. Connolly, J. Pogue, and R. Hart Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
60. R. Mehran, S.V. Rao, and D.L. Bhatt Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
61. G. Ndrepepa, T. Schuster, and M. Hadamitzky Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention Circulation 125 2012 1424 1431
62. M. Valgimigli, G. Campo, and M. Monti Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 2012 2015 2026
63. F.W. Verheugt, S.R. Steinhubl, and M. Hamon Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention JACC Cardiovasc Interv 4 2011 191 197
64. S.S. Jolly, S. Yusuf, and J. Cairns Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial Lancet 377 2011 1409 1420
65. E. Romagnoli, G. Biondi-Zoccai, and A. Sciahbasi Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study J Am Coll Cardiol 60 2012 2481 2489